Last updated: May 6, 2026
In this article
- What Are Mast Cell Tumors in Dogs?
- What Do Mast Cell Tumors Look Like?
- Diagnosing Mast Cell Tumors: Fine Needle Aspirate (FNA)
- Mast Cell Tumor Grades: Understanding the Grading System
- Staging: How Far Has the Cancer Spread?
- Surgical Treatment: The Importance of Wide Margins
- Chemotherapy for Mast Cell Tumors
- Radiation Therapy
- Palladia (Toceranib Phosphate)
- Dog Breeds at Higher Risk for Mast Cell Tumors
- Prognosis by Tumor Grade
- Monitoring for New Lumps
- Frequently Asked Questions
A lump on your dog’s skin is always worth investigating, but some lumps carry more urgency than others. Mast cell tumors are the most common malignant skin tumors in dogs, accounting for roughly 20 percent of all skin cancers diagnosed in the species. They can range from small, slow-growing bumps that are easily cured with surgery to aggressive, life-threatening cancers that spread to internal organs. Understanding what a mast cell tumor is, how it is graded, and what treatment options are available can help you make informed decisions alongside your veterinarian and give your dog the best possible outcome.
What Are Mast Cell Tumors in Dogs?
Mast cells are a normal part of the immune system. They are found throughout the body — in the skin, respiratory tract, gastrointestinal tract, and other tissues — and they play a role in allergic responses, wound healing, and defense against parasites. Mast cells contain granules filled with biologically active chemicals, including histamine, heparin, and various enzymes. Under normal circumstances, these chemicals are released in controlled amounts as part of an immune response.
A mast cell tumor (MCT) forms when mast cells begin to grow and divide uncontrollably. The resulting mass retains the ability to release those granules, which is what makes mast cell tumors uniquely unpredictable. When an MCT is handled, bumped, or biopsied, the mechanical disturbance can trigger degranulation — the sudden release of histamine and other chemicals — which can cause localized swelling, redness, and irritation around the tumor. In severe cases, widespread degranulation can lead to systemic effects such as stomach ulcers, dangerously low blood pressure, and abnormal blood clotting. This phenomenon is one of the reasons mast cell tumors are taken so seriously even when they appear small or benign on the surface.
What Do Mast Cell Tumors Look Like?
One of the most frustrating things about mast cell tumors is that they have no single characteristic appearance. They are sometimes called “the great pretender” because they can mimic almost any other type of skin lump. Some mast cell tumors present as small, firm, hairless nodules that sit just beneath the skin surface. Others appear as soft, fleshy, raised masses that may be red or ulcerated. Some look like insect bites or warts. Others are flat and barely noticeable.
A common behavior of MCTs is a phenomenon called the Darier sign — the tumor changes in size, sometimes dramatically, over hours or days. It may swell after being touched or after a period of activity, then shrink back down. This waxing and waning pattern is caused by localized degranulation and histamine release. If you notice a lump on your dog that seems to grow and shrink, that inconsistency itself is a red flag that warrants prompt veterinary evaluation.
Mast cell tumors most commonly appear on the trunk, limbs, and around the genital area, but they can develop anywhere on the body, including the head, neck, and inside the mouth. Some dogs develop a single MCT in their lifetime, while others develop multiple tumors at different sites over months or years.
Diagnosing Mast Cell Tumors: Fine Needle Aspirate (FNA)
The good news about mast cell tumors is that they are often straightforward to identify with a simple, minimally invasive test. A fine needle aspirate (FNA) involves inserting a small needle into the lump to withdraw a sample of cells, which are then spread onto a glass slide and examined under a microscope. Mast cells have a distinctive appearance — they are round cells filled with dark-staining granules — and an experienced veterinarian or pathologist can often identify them on cytology within minutes.
An FNA can confirm that a lump is a mast cell tumor, but it generally cannot tell you the grade. For grading — which is critical for determining treatment and prognosis — the entire tumor typically needs to be removed and submitted for histopathology. This means that even after a positive FNA, surgery is usually the recommended next step, both to remove the tumor and to obtain a complete tissue sample for grading.
Because any lump on a dog could potentially be an MCT, veterinarians widely recommend aspirating new lumps rather than simply watching them. Early identification of a mast cell tumor can make the difference between a straightforward surgical cure and a much more complicated treatment course. If you are considering adopting a dog, particularly one of the breeds more susceptible to MCTs, establishing a relationship with a veterinarian who can evaluate lumps promptly is an important part of responsible ownership. You can browse dogs looking for homes on our adoption page.
Mast Cell Tumor Grades: Understanding the Grading System
The grade of a mast cell tumor is determined by a pathologist who examines the surgically removed tumor under a microscope. Grading looks at cellular characteristics — how differentiated the cells are, how rapidly they are dividing, and how deeply they invade surrounding tissue. Two grading systems are in common use. The Patnaik system divides MCTs into three grades (I, II, and III), while the newer Kiupel two-tier system classifies them as either low grade or high grade. Many oncologists use both systems together, as each provides useful information.
Grade I (Low Grade / Well-Differentiated)
Grade I mast cell tumors are the least aggressive form. The cells are well differentiated, meaning they closely resemble normal mast cells. They are typically confined to the skin, grow slowly, and have a low rate of cell division. Under the Kiupel system, these tumors fall into the low-grade category. Grade I MCTs are generally cured by complete surgical excision, and recurrence or metastasis is uncommon. The prognosis for dogs with grade I tumors is excellent, with survival times often measured in years.
Grade II (Intermediate Grade / Moderately Differentiated)
Grade II tumors represent the largest and most variable category under the Patnaik system. The cells are moderately differentiated — they retain some characteristics of normal mast cells but also show signs of abnormality, including a higher rate of cell division. Grade II tumors can behave unpredictably. Some are relatively low risk and are managed successfully with surgery alone, while others are more aggressive with a greater tendency to recur locally or spread to lymph nodes. Because this category covers such a wide spectrum of biological behavior, additional testing — including the mitotic index, Ki67 staining, and c-KIT mutation analysis — is often performed on grade II tumors to help predict how a specific tumor is likely to behave. Under the Kiupel system, grade II tumors may be classified as either low grade or high grade depending on these additional markers.
Grade III (High Grade / Poorly Differentiated)
Grade III mast cell tumors are the most aggressive form. The cells are poorly differentiated, meaning they bear little resemblance to normal mast cells. They divide rapidly, invade deeply into surrounding tissue, and have a high rate of metastasis to lymph nodes, spleen, liver, and bone marrow. Under the Kiupel system, these tumors are classified as high grade. The prognosis for grade III MCTs is guarded. Even with aggressive multimodal treatment, median survival times are typically measured in months rather than years. However, treatment can meaningfully extend and improve quality of life, and some dogs do achieve longer-term remission.
Staging: How Far Has the Cancer Spread?
While grading tells you how aggressive the tumor cells are, staging tells you whether the cancer has spread beyond the original site. Staging is particularly important for grade II and grade III tumors, where the likelihood of metastasis is higher. A typical staging workup for a mast cell tumor includes:
- Regional lymph node aspirate — the lymph node closest to the tumor (the sentinel node) is aspirated to check for mast cell infiltration
- Abdominal ultrasound — to evaluate the spleen and liver, which are common sites for MCT metastasis
- Splenic and hepatic aspirates — if the spleen or liver appear abnormal on ultrasound, fine needle aspirates can confirm or rule out mast cell involvement
- Buffy coat smear — a blood test that checks for circulating mast cells
- Bone marrow aspirate — reserved for advanced cases where bone marrow involvement is suspected
Staging helps determine the appropriate level of treatment. A low-grade tumor that has not spread may need nothing beyond surgery, while a tumor that has reached the lymph nodes or internal organs will likely require systemic therapy in addition to surgery.
Surgical Treatment: The Importance of Wide Margins
Surgery is the primary treatment for most mast cell tumors and, when performed correctly, it is often curative for grade I and many grade II tumors. The key to successful MCT surgery is achieving wide surgical margins — removing not just the visible tumor but a significant border of normal-appearing tissue around it. Mast cell tumors are known for extending microscopic tendrils of cancer cells into surrounding tissue well beyond what is visible or palpable. If these cells are left behind, the tumor will almost certainly regrow at the same site.
Current surgical recommendations for mast cell tumors call for lateral margins of two to three centimeters on all sides and a deep margin of one fascial plane beneath the tumor. This means the resulting wound is substantially larger than the tumor itself, and the surgery may require advanced closure techniques such as skin flaps or grafts, particularly for tumors in locations where there is limited loose skin, such as the lower legs or the head.
After surgery, the excised tissue is sent to a pathologist for histopathology. The pathologist evaluates the margins — the outer edges of the tissue — to determine whether cancer cells are present at the borders. If the margins are “clean” (no cancer cells at the edges), the tumor is considered completely excised and the risk of local recurrence is low. If the margins are “dirty” or “narrow” (cancer cells at or near the edges), additional treatment is needed. This may involve a second surgery to take wider margins, or radiation therapy to the surgical site.
Chemotherapy for Mast Cell Tumors
Chemotherapy is recommended for dogs with high-grade (grade III) mast cell tumors, tumors that have spread to lymph nodes or internal organs, or tumors that cannot be completely removed surgically. The goal of chemotherapy in MCT treatment is typically to slow disease progression and extend survival time rather than to achieve a complete cure, though some dogs do achieve lasting remission.
The most commonly used chemotherapy protocols for canine MCTs include vinblastine combined with prednisone, and lomustine (CCNU). Vinblastine-prednisone protocols are generally well tolerated by most dogs, with manageable side effects that may include mild gastrointestinal upset and temporary drops in white blood cell counts. Lomustine can be more aggressive and requires careful monitoring of liver enzymes and blood counts. Your veterinary oncologist will recommend the protocol best suited to your dog’s specific situation based on the tumor grade, stage, and overall health.
It is worth noting that chemotherapy in dogs is generally less intensive than chemotherapy in humans. The goal is to maintain quality of life, and most dogs tolerate treatment well without the severe side effects that people often associate with the word “chemo.” Many dogs continue their normal routines — eating, playing, and enjoying life — throughout their treatment course.
Radiation Therapy
Radiation therapy is most commonly used for mast cell tumors that have been incompletely excised — that is, when histopathology reveals cancer cells at the surgical margins and a second surgery is not feasible or practical. Radiation can also be used as a primary treatment for tumors in locations where surgery would be difficult or disfiguring.
For incompletely excised grade I and grade II tumors, radiation therapy to the surgical site is highly effective, with local control rates exceeding 90 percent in many studies. Treatment typically involves a series of sessions (fractions) delivered over several weeks, usually requiring brief anesthesia for each session to ensure precise targeting. Side effects are generally limited to the treated area and may include skin redness, hair loss, and temporary irritation that resolves after treatment is complete.
Palladia (Toceranib Phosphate)
Palladia (toceranib phosphate) is an oral targeted therapy drug that was specifically developed for the treatment of canine mast cell tumors. It is a tyrosine kinase inhibitor (TKI) — a type of drug that blocks specific proteins involved in tumor cell growth and the formation of new blood vessels that feed the tumor. Palladia was the first cancer drug approved by the FDA specifically for use in dogs.
Palladia is most commonly prescribed for mast cell tumors that have recurred after surgery, tumors that cannot be surgically removed, or as part of a multimodal treatment plan for aggressive MCTs. It can be used alone or in combination with other therapies. Response rates vary, but approximately 40 to 60 percent of dogs show measurable tumor shrinkage or stabilization of disease on Palladia.
Side effects of Palladia can include gastrointestinal symptoms (decreased appetite, vomiting, diarrhea), protein in the urine, lameness, and less commonly, bleeding disorders. The drug is given on an every-other-day or Monday-Wednesday-Friday schedule, and regular monitoring through blood work and urinalysis is required. Most side effects are manageable with dose adjustments and supportive care. Because Palladia can be absorbed through the skin, owners must wear gloves when handling the tablets and follow safety precautions for disposal.
Dog Breeds at Higher Risk for Mast Cell Tumors
While any dog of any breed or mix can develop a mast cell tumor, certain breeds have a documented genetic predisposition. Breeds with elevated MCT risk include:
- Boxers — the breed most commonly associated with mast cell tumors, though their MCTs tend to be lower grade with better prognoses
- Boston Terriers — similar to Boxers, frequently affected but often with lower-grade tumors
- Labrador Retrievers — common breed affected, variable tumor grades
- Golden Retrievers — predisposed to multiple cancer types including MCTs
- Pugs — frequently develop multiple MCTs, often low grade
- Bulldogs — brachycephalic breeds in general carry elevated risk
- Pit Bull Terriers — higher incidence with variable behavior
- Weimaraners — predisposed to higher-grade tumors in some studies
- Rhodesian Ridgebacks — elevated risk with variable tumor grades
- Shar-Peis — tend to develop more aggressive MCTs at younger ages
- Staffordshire Bull Terriers — similar risk profile to other bull breeds
If you own or are considering adopting one of these breeds, awareness of mast cell tumors should be part of your preventive health plan. Familiarize yourself with your dog’s normal skin and body so that you can detect new lumps early. You can learn more about these and other breeds in our dog breeds directory.
Prognosis by Tumor Grade
The grade of a mast cell tumor is the single strongest predictor of outcome. While every case is individual and other factors — including tumor location, stage, completeness of surgical excision, and whether a c-KIT mutation is present — also influence prognosis, the following general guidelines apply:
Grade I / Low Grade: The prognosis is excellent. With complete surgical excision, the vast majority of dogs are cured. Median survival times exceed three to five years, and many dogs live out their normal life span without recurrence. Additional treatment beyond surgery is rarely needed.
Grade II / Intermediate: The prognosis is variable and depends heavily on additional prognostic indicators. Grade II tumors with a low mitotic index (fewer than 5 mitotic figures per 10 high-power fields) that are completely excised carry a prognosis approaching that of grade I tumors. Grade II tumors with a high mitotic index, incomplete margins, or evidence of spread have a more guarded prognosis, with median survival times ranging from roughly one to three years depending on the specifics. These tumors often benefit from adjuvant therapy such as radiation or chemotherapy.
Grade III / High Grade: The prognosis is guarded to poor. Even with aggressive multimodal therapy — surgery plus chemotherapy and/or radiation — median survival times typically range from six to twelve months. Some dogs exceed these averages, particularly if the tumor is caught early, completely removed, and followed with appropriate systemic therapy. However, the aggressive biological behavior of grade III tumors means that recurrence and metastasis are common challenges.
Monitoring for New Lumps
Dogs that have been diagnosed with one mast cell tumor are at increased risk of developing additional MCTs in the future. This is not necessarily metastasis — they may be entirely new, independent tumors arising from different populations of mast cells. For this reason, ongoing monitoring is essential even after successful treatment.
Get into the habit of performing a thorough hands-on exam of your dog at least once a month. Run your hands over the entire body, paying attention to areas under the legs, around the groin, on the belly, behind the ears, and between the toes. Note the size and location of any existing lumps and watch for changes. Any new lump, or any existing lump that changes in size, shape, or texture, should be evaluated by your veterinarian promptly. Many veterinarians recommend mapping a dog’s lumps — recording the location and size of each known mass — so that changes over time are easier to track.
Regular veterinary checkups, typically every three to six months for the first two years after MCT treatment, help catch recurrences or new tumors early when treatment options are most effective. Your veterinarian may also recommend periodic abdominal ultrasounds and lymph node checks as part of the monitoring protocol, particularly for dogs that had higher-grade tumors.
While a mast cell tumor diagnosis can be frightening, it is important to remember that many dogs — particularly those with grade I and low-risk grade II tumors — go on to live full, comfortable lives after treatment. Early detection, appropriate surgery with adequate margins, and a clear understanding of your dog’s specific tumor grade and stage are the foundation of the best possible outcome. If you are looking to give a loving home to a dog in need, including those that may require a little extra veterinary attention, visit our adoption page to see pets currently available.
Frequently Asked Questions
How long can a dog live with a mast cell tumor?
Survival depends almost entirely on the tumor’s grade and how early it is treated. Dogs with grade I or low-grade tumors that are completely removed surgically often live their full natural life span. Dogs with grade II tumors typically survive one to several years depending on additional prognostic factors. Dogs with grade III tumors have median survival times of six to twelve months with treatment, though individual outcomes vary.
Are mast cell tumors in dogs always cancerous?
Yes, mast cell tumors are classified as malignant (cancerous) by definition, even low-grade ones. However, their biological behavior ranges enormously. Many low-grade MCTs behave in a benign fashion and are effectively cured with surgery alone. The term “malignant” reflects the potential for aggressive behavior rather than a guarantee of it.
Can mast cell tumors in dogs appear suddenly?
Yes. Some MCTs seem to appear overnight or grow rapidly over a matter of days. Others grow slowly over weeks or months. The waxing and waning pattern caused by histamine release can also make a tumor appear to come and go, which may delay diagnosis. Any new lump that appears suddenly on your dog should be aspirated by a veterinarian.
Is surgery always necessary for mast cell tumors?
Surgery is the gold-standard treatment whenever it is feasible. Complete surgical excision with wide margins offers the best chance of cure for grade I and grade II tumors. In cases where surgery is not possible — due to tumor location, the dog’s overall health, or the extent of disease — alternatives such as radiation therapy, Palladia, or chemotherapy may be used to manage the tumor.
What should I do if I find a new lump on my dog?
Schedule a veterinary appointment for a fine needle aspirate as soon as possible. Do not adopt a wait-and-see approach with lumps, as early diagnosis of a mast cell tumor significantly improves the outcome. An FNA is a quick, inexpensive, and low-risk procedure that can provide critical information about what the lump is and how urgently it needs to be addressed.
Can diet or supplements help prevent mast cell tumors?
There is no proven dietary intervention that prevents mast cell tumors. However, maintaining your dog at a healthy weight, feeding a balanced diet, and minimizing unnecessary exposure to environmental toxins are general health practices that support the immune system. Some veterinary oncologists recommend omega-3 fatty acid supplementation for dogs undergoing cancer treatment, as these may have mild anti-inflammatory and anti-tumor properties, but this should be discussed with your veterinarian.